SCHEMBL10401768

SCHEMBL10401768

N#Cc1ccc(Br)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
GLA P06280 1/20 0.53
MYC P01106 1/20 0.45
NR4A1 P22736 1/20 0.45
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GPR35 Q9HC97 1/20 0.44
SORT1 Q99523 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43
APEX1 P27695 1/20 0.42
CES2 O00748 1/20 0.42
GALR3 O60755 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
CASP1 P29466 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257347 0.85 KDM4E (0.48) KDM4EGLAMYCNR4A1GRIN1
Benzene SCHEMBL28354519 0.79 KDM4E (0.52) KDM4EGLAMYCNR4A1GRIN1
SCHEMBL27726722 0.79 NR4A2 (0.48) KDM4EGLACYP1A2CYP2C9HPGD
SCHEMBL29746327 0.79 NR4A2 (0.48) KDM4EGLACYP1A2CYP2C9HPGD
SCHEMBL19332613 0.79 POLB (0.46) KDM4ECES2GALR3CYP1A2CYP2C9
SCHEMBL2820180 0.78 ALDH1A1 (0.49) KDM4EMRGPRX4HPGDALDH1A1
SCHEMBL7196160 0.78 XDH (0.46) KDM4EMRGPRX4HTT
SCHEMBL16956874 0.78 MAOB (0.42) KDM4ECES2GALR3CYP1A2CYP2C9
SCHEMBL24824531 0.77 MRGPRX4 (0.59) KDM4EMYCNR4A1MRGPRX4CASP1
SCHEMBL1110956 0.77 KEAP1 (0.53) MRGPRX4CES2MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105001213-B C-aryl glycoside derivative, pharmaceutical composition, preparation method and application thereof 上海迪诺医药科技有限公司 2020-08-28 CN disclosed
EP-3426260-A1 C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE Fimbrion Therapeutics, Inc. (US) 2019-01-16 EP disclosed
US-9914724-B2 C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-03-13 US disclosed
US-9914724-B2 C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-03-13 US disclosed
US-9914724-B2 C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-03-13 US disclosed
WO-2017156508-A1 C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE FIMBRION THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed
WO-2017156508-A1 C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE FIMBRION THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed
EP-3133071-A1 C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF Shanghai De Novo Pharmatech Co Ltd. (CN) 2017-02-22 EP disclosed
EP-3133071-A1 C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF Shanghai De Novo Pharmatech Co Ltd. (CN) 2017-02-22 EP disclosed
US-20170037038-A1 C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) 2017-02-09 US disclosed
US-20170037038-A1 C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) 2017-02-09 US disclosed
US-20170037038-A1 C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) 2017-02-09 US disclosed
WO-2015158206-A1 C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF 上海迪诺医药科技有限公司 2015-10-22 WO disclosed
US-4946858-A ANTIDIABETIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1990-08-07 US disclosed
US-4900739-A ANTIDIABETIC AGENTS AMERICAN HOME PRODUCTS CORP. (US) 1990-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037038-A1 C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF SLC5A2, SLC5A1, MGAT1 KDM4E 1326/4885GLA 290/4885MYC 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.